Evidence map›Paper›PMID 40576431›Full record

ReviewScience progress

Research progress of polysaccharide drug delivery systems in the treatment of intestinal diseases: A review.

Ling Dong, Huiying He, Xuexia Liu, Shuang Ma, Ruying Qiao, Zanwen Peng, Wencong Liu

Abstract readReview
In one paragraph

Review in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ling DongSchool of Food and Pharmaceutical Engineering, Wuzhou University, Wuzhou, China.
Huiying HeCollege of Resources and Environment, Jilin Agricultural University, Changchun, China.ORCID 0009-0005-6276-1416
Xuexia LiuWuzhou Traditional Chinese Medicine Hospital, Guangxi Zhuang Autonomous Region, Wuzhou, China.
Shuang MaSchool of Food and Pharmaceutical Engineering, Wuzhou University, Wuzhou, China.
Ruying QiaoSchool of Food and Pharmaceutical Engineering, Wuzhou University, Wuzhou, China.
Zanwen PengLiupao Tea Modern Industry College, Wuzhou University, Wuzhou, China.
Wencong LiuSchool of Food and Pharmaceutical Engineering, Wuzhou University, Wuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intestinal diseases (IDs), as a type of complex immune-related diseases, have long faced challenges such as low drug delivery efficiency, insufficient targeting, and significant systemic toxic and side effects in their treatment strategies. Although oral administration is widely adopted due to its noninvasiveness and high patient compliance, the heterogeneity of the gastrointestinal environment severely limits the precise release and effective accumulation of drugs in the colon. Therefore, developing a new type of drug carrier system that can overcome physiological barriers and achieve colonic targeted delivery has become one of the core research directions in the field of ID therapy. Drug delivery systems based on natural polysaccharides have received extensive attention due to their unique biocompatibility, modifiers, and environmental response characteristics. Polysaccharides not only have excellent drug loading capacity but also can respond to the specific pH value, enzyme environment, and redox state of the colon through chemical modification or physical embedding strategies, thereby precisely regulating drug release kinetics. This article reviews the therapeutic effect of polysaccharide delivery systems in IDs, providing more approaches for the treatment of ID.

Indexed as

Drug CarriersDrug Delivery SystemsIntestinal DiseasesPolysaccharidesAnimalsDrug LiberationHumansDrug CarriersPolysaccharidescolon-targeted drug deliveryintestinal diseasesmicron particle systemsnanoparticle systemsNatural polysaccharides

Identifiers

PMID40576431
PMCPMC12205205

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.